300519.SHE Zhejiang Xinguang Pharmaceutical Co Ltd
- Market cap
- CNY 2.32B
- P/E
- 30.2x
- P/B
- 2.60x
- ROE
- 10.0%
- Dividend yield
- 2.07%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300519.SHE undervalued?
Graham number300519.SHE trades 87.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Xinguang Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Xinguang Pharmaceutical Co Ltd yet.
Zhejiang Xinguang Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Xinguang Pharmaceutical Co Ltd
Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers Chinese patent medicines, chemical medicines, and health food in various forms, including tablets, mixtures, granules, syrups, powders, hard capsules, and oral liquids, as well as drinks. Its products are used for the treatment of cardiovascular, trauma, respiratory, digestive, urinary, pediatric, and immuni…
Full company profileZhejiang Xinguang Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Xinguang Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 315M | 311M | 276M | 291M | 283M | 321M | 351M | 270M | 268M | 265M | 281M |
| Gross Profit | 204M | 186M | 151M | 158M | 154M | 176M | 182M | 110M | 89.8M | 103M | 141M |
| Operating Income | 132M | 123M | 101M | 109M | 112M | 133M | 127M | 74.1M | 57.3M | 48.4M | 92.2M |
| EBITDA | 145M | 129M | 115M | 118M | 127M | 145M | 140M | 87.9M | 72.0M | 63.1M | 92.2M |
| Net Income | 119M | 106M | 88.0M | 93.9M | 99.0M | 114M | 109M | 64.4M | 50.4M | 54.2M | 85.5M |
| EPS | 0.89 | 0.66 | 0.55 | 0.59 | 0.62 | 0.71 | 0.68 | 0.40 | 0.31 | 0.34 | 0.53 |
| Balance Sheet | |||||||||||
| Total Assets | 701M | 775M | 822M | 861M | 891M | 932M | 958M | 930M | 910M | 889M | 910M |
| Total Liabilities | 60.5M | 69.2M | 69.2M | 61.4M | 63.8M | 86.2M | 98.9M | 86.3M | 79.2M | 52.6M | 55.8M |
| Shareholders' Equity | 640M | 706M | 753M | 800M | 827M | 846M | 859M | 844M | 831M | 837M | 854M |
| Cash & Short-term Investments | 337M | 377M | 406M | 625M | 677M | 719M | 737M | 699M | 688M | 312M | 379M |
| Total Debt | 2.36M | 2.36M | 2.36M | 2.36M | - | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 121M | 124M | 92.8M | 98.3M | 113M | 142M | 126M | 53.3M | 53.4M | 68.9M | - |
| Capital Expenditure | 22.3M | 30.4M | 21.3M | 16.0M | 10.3M | 14.7M | 16.6M | 16.0M | 5.20M | 3.48M | 533K |
| Free Cash Flow | 98.9M | 93.8M | 71.5M | 82.3M | 102M | 128M | 110M | 37.3M | 48.2M | 65.4M | 98.4M |
| Ratios | |||||||||||
| ROE | 18.6% | 15.0% | 11.7% | 11.7% | 12.0% | 13.5% | 12.7% | 7.6% | 6.1% | 6.5% | 10.0% |
| ROA | 17.0% | 13.7% | 10.7% | 10.9% | 11.1% | 12.3% | 11.4% | 6.9% | 5.5% | 6.1% | 9.4% |
| Net Profit Margin | 37.7% | 34.1% | 31.9% | 32.2% | 35.0% | 35.6% | 31.0% | 23.8% | 18.8% | 20.4% | 30.4% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Xinguang Pharmaceutical Co Ltd dividends
- Dividend yield
- 2.07%
- Forward dividend
- 0.30 CNY
- Payout ratio
- 88.5%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 48.0M | 0.30 | 88.5% |
| 2024 | CNY 64.0M | 0.39 | 127.0% |
| 2023 | CNY 80.0M | 0.50 | 124.3% |
| 2022 | CNY 96.0M | 0.60 | 88.2% |
| 2021 | CNY 96.0M | 0.60 | 84.0% |
| 2020 | CNY 72.0M | 0.45 | 72.7% |
| 2019 | CNY 48.0M | 0.30 | 51.1% |
| 2018 | CNY 40.0M | 0.25 | 45.5% |
| 2017 | CNY 40.0M | 0.25 | 37.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Jul 4, 2017.
Who owns Zhejiang Xinguang Pharmaceutical Co Ltd
- Insiders 53.51%
- Institutions 2.78%
- Public & others 43.71%
- Shares outstanding 160M
- Free float 78.0M
Zhejiang Xinguang Pharmaceutical Co Ltd company profile
- Company name
- Zhejiang Xinguang Pharmaceutical Co Ltd
- Ticker
- 300519.SHE
- ISIN
- CNE1000027T3
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 309
- Fiscal year end
- December
- Address
- No. 25, Huancheng West Road, Shengzhou, China, 312400
- Phone
- 86 575 8329 2898
- Website
- xgpharma.com
About Zhejiang Xinguang Pharmaceutical Co Ltd
Zhejiang Xinguang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals in China and internationally. The company offers Chinese patent medicines, chemical medicines, and health food in various forms, including tablets, mixtures, granules, syrups, powders, hard capsules, and oral liquids, as well as drinks. Its products are used for the treatment of cardiovascular, trauma, respiratory, digestive, urinary, pediatric, and immunity diseases. The company was incorporated in 1998 and is headquartered in Shengzhou, China.
Zhejiang Xinguang Pharmaceutical Co Ltd management
4- Mr. Yue Jun WangChairman & GM · born 1954
- Ms. Bin Bin XingCFO, Accounting Supervisor & Director · born 1975
- Mr. Fu Yin QiuDeputy GM & Director · born 1962
- Mr. Yuan Yang JiangDeputy GM, Secretary of the Board & Director · born 1968